MedPath
Found 4 clinical trials|View Analysis
Sort by:

Integrated Pharmacokinetics (PK)/efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination with Yervoy®

Phase 3
Not yet recruiting
Conditions
Melanoma
Interventions
Drug: JPB898 (Induction and Maintenance)
Drug: Opdivo-EU (Induction)
Drug: Opdivo-US (Induction)
Drug: Yervoy-EU (Induction)
Drug: Opdivo-EU (Maintenance)
First Posted Date
2024-09-09
Last Posted Date
2024-09-13
Lead Sponsor
Sandoz
Target Recruit Count
720
Registration Number
NCT06587451

An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany

Recruiting
Conditions
Resectable Non-small Cell Lung Cancer
Interventions
Drug: Neoadjuvant nivolumab in combination with platinum-based chemotherapy
First Posted Date
2023-12-14
Last Posted Date
2024-04-18
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
400
Registration Number
NCT06169956
Locations
🇩🇪

Klinikverbund Allgaeu, Kempten, Bayern, Germany

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

Phase 1
Recruiting
Conditions
Solid Tumor, Adult
Refractory Cancer
Recurrent Cancer
Cancer
Interventions
Biological: IMA203 Product
Biological: IMA203 product- flat dose
Biological: IMA203CD8 Product
Device: IMADetect®
Drug: nivolumab (Opdivo®)
First Posted Date
2018-09-26
Last Posted Date
2024-11-25
Lead Sponsor
Immatics US, Inc.
Target Recruit Count
476
Registration Number
NCT03686124
Locations
🇩🇪

Klinikum rechts der Isar der Technischen Universität München, Munich, Bavaria, Germany

🇺🇸

University of Miami Hospital and Clinics, Miami, Florida, United States

🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

and more 9 locations

Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers

Phase 1
Completed
Conditions
Ewing Sarcoma
PEComa
Epithelioid Sarcoma
Desmoid Tumor
Chordoma
Non Small Cell Lung Cancer
Urothelial Carcinoma
Melanoma
Renal Cell Carcinoma
Hepatocellular Carcinoma
Interventions
Drug: Nab-Rapamycin
Biological: Nivolumab
First Posted Date
2017-06-16
Last Posted Date
2021-12-06
Lead Sponsor
Sarcoma Oncology Research Center, LLC
Target Recruit Count
34
Registration Number
NCT03190174
Locations
🇺🇸

Sarcoma Oncology Research Center, Santa Monica, California, United States

© Copyright 2025. All Rights Reserved by MedPath